Granulocyte colony-stimulating factor (G-CSF) not only increases neutrophil (polymorphonuclear leukocyte, PMNL) production but also modulates PMNL biologic function. To assess the ability of G-CSF administered in vivo to enhance PMNL activity against opportunistic fungal pathogens, the antifungal activity of PMNL obtained from normal human volunteers before and after G-CSF administration was compared. In vivo, G-CSF significantly enhanced PMNL-mediated killing of Aspergillus fumigatus and Rhizopus arrhizus by 4-fold and 15-fold, respectively (P õ .05). In contrast, PMNL-mediated killing of Candida albicans was unaffected by G-CSF. The ability of aqueous fungal extracts to induce the PMNL respiratory burst was evaluated by luminol-enhanced chemiluminescence. G-CSF in vivo primed PMNL for sustained chemiluminescence in response to extracts of Candida, Aspergillus, and Rhizopus organisms. These data demonstrate that G-CSF in vivo augments antifungal activities of PMNL, thereby implicating a possible therapeutic role for G-CSF as a biologic response-modifying agent during opportunistic fungal infection.
Neutrophils (polymorphonuclear leukocytes, PMNL) reprethe ability of G-CSF in vitro to promote PMNL-mediated killing of C. albicans have yielded variable results [6] [7] [8] [9] . This increase sent the first and most important line of host defense against pathogenic opportunistic fungi in humans [1, 2] . Prolonged in PMNL-mediated activity against C. albicans has been attributed, at least in part, to G-CSF priming of the inducible respiratory neutropenia and neutrophil dysfunction are among the strongest predictors for serious, life-threatening infections from these (or oxidative) burst [4] [5] [6] 10] . Similar effects have been observed in studies examining the effect of G-CSF in vitro on fungicidal agents [1] . Despite aggressive antimicrobial therapy, severe morbidity and mortality are common clinical sequelae of these activity of both normal and defective PMNL against Aspergillus fumigatus, a medically important opportunistic mold [11] [12] [13] . infections.
Recent studies have demonstrated that granulocyte colony-stimThese results suggest that G-CSF may serve as a clinically useful immunomodulatory agent for the prevention and treatment of ulating factor (G-CSF) not only increases the production of PMNL but also modulates the functional activity of developing and maopportunistic fungal infections in selected patient populations [3] [4] [5] [6] [8] [9] [10] [11] [12] [13] . ture PMNL [3] . When PMNL from human immunodeficiency virus (HIV)-infected or bone marrow transplant patients are coWhile the effects of G-CSF in vitro on PMNL-mediated antifungal activity have been well documented, the ability of cultivated with G-CSF in vitro, enhanced killing of Candida albicans has been observed [4, 5] . However, investigations examining G-CSF administered in vivo to modulate PMNL antifungal activity has received less attention in published reports. To assess whether G-CSF in vivo potentiates PMNL antifungal activity, we performed the present study, in which PMNL were obtained from normal human volunteers both before and after ent of a medical student summer research fellowship from Amgen (Thousand Oaks, CA). The study was supported by NIH (HL-53515, HL-36444, and CA-18029). Recombinant human granulocyte colony-stimulating factor was supplied by Amgen. Study design. Three normal human volunteers recruited from the community (age, 24-35 years; weight, 65-74 kg) received 300 mg of G-CSF subcutaneously each morning for 5 consecutive days. All of the volunteers were nonsmokers, had normal physical examinations, were receiving no concomitant medications, and had not experienced an acute illness during the 6 weeks preceding the study. All volunteers underwent laboratory screening.
Materials and Methods
PMNL purification. Venous blood was collected from the normal human volunteers on day 0 before G-CSF administration and on day 6 (following administration of G-CSF for 5 consecutive days) and 24 h after the last dose of G-CSF, using 0.2% dipotassium EDTA as anticoagulant. PMNL were isolated by sequential sedimentation in Dextran T-500 (Pharmacia LKB Biotechnology, Piscataway, NJ) in 0.9% sodium chloride, centrifugation in Histopaque-1077 (Sigma, St Louis), and hypotonic lysis of erythrocytes Figure 1 . Administration of G-CSF in vivo increases neutrophil as described [14] . Cell viability was ú98% as determined by (polymorphonuclear leukocyte, PMNL)-mediated microbicidal activtrypan blue exclusion.
ity against opportunistic fungi. Fungicidal activity of PMNL against conidia of Candida albicans, Aspergillus fumigatus, and Rhizopus Aqueous fungal extracts. Fungal extracts were prepared by arrhizus was evaluated by colony-forming unit inhibition assay in filter separation of culture filtrates. Conidia from C. albicans, A.
PMNL isolated from venous blood of 3 normal human volunteers fumigatus, and R. arrhizus were grown separately in 1-L volumes before and after administration of G-CSF in vivo. Data represent of RPMI 1640 (American Biorganics, Niagara Falls, NY) for 7 mean { SD. * Significant difference in fungicidal activity compared days at 37ЊC with constant aeration. The predominant growth with control PMNL (P õ .05). forms of the mycelia under these conditions were blastospores for C. albicans, conidia for A. fumigatus, and sporangiospores for R. arrhizus. However, hyphae were easily visible in all aliquots examined. The culture supernatant was separated from the mycelial Results mat by vacuum filtration through a sterile 0.2-mm pore size disposable filter (Zapcap-S; Schleicher & Schuell, Keene, NH), followed
The absolute neutrophil count (ANC) in the venous blood by a single wash with 500 mL of sterile water. This final filtrate of the 3 normal volunteers increased from a mean baseline product, designated as ''extract,'' was frozen at 020ЊC in 2-mL value of 4025/mL (range, 2948-5346/mL) before administraaliquots until use. Protein concentrations of the fungal extracts tion of G-CSF to a mean value of 24,878/mL (range, 18,330-were measured colorimetrically (BCA protein assay reagent; Pierce, Rockford, IL).
31,020/mL) on day 6 of the protocol after 5 consecutive daily Luminol-enhanced chemiluminescence. Luminol-enhanced doses of G-CSF. This increase in ANC induced by G-CSF in chemiluminescence was used as a sensitive measure of the respiravivo was predominantly due to a large increase in morphologitory burst of PMNL as previously described [15] . At the start of cally mature PMNL. Bands were the least mature granulocytes the assay, 10 mM luminol and the designated fungal extract (100 identified in the peripheral blood smear and accounted for õ5% ng of protein/mL) was added to the reaction mixture containing of the ANC in each volunteer at the end of the protocol. The The ability of G-CSF to prime the PMNL respiratory burst in different following administration of G-CSF in vivo. In contrast to the relatively brief chemiluminescence primed by G-CSF in response to aqueous extracts from both the hyphal and conidial forms of opportunistic fungi was evaluated by luminol-envitro, administration of G-CSF in vivo resulted in a population of PMNL capable of undergoing a sustained chemilumineshanced chemiluminescence (figure 2). Negligible chemiluminescence was induced in control PMNL in response to extracts cence, which was still evident 90 min after stimulation by each of the fungal extracts ( figure 2A ). of C. albicans, A. fumigatus, and R. arrhizus. When control PMNL were preincubated for 60 min with G-CSF (1 mg/mL) in
The maximal rate of PMNL chemiluminescence induced by specific fungal extracts was differentially affected by G-CSF vitro, each of these extracts induced a rapid chemiluminescence response, which peaked at 10-15 min and declined to baseline in vitro and in vivo (figure 2B). Although peak PMNL chemiluminescence in response to each fungal extract was significantly values by 60 min. Chemiluminescence kinetics were markedly
